Search

Your search keyword '"Mehta, Shamir"' showing total 36 results
Start Over Author "Mehta, Shamir" Publisher wiley
36 results on '"Mehta, Shamir"'

4. Safety and efficacy of the bioabsorbable polymer everolimus‐eluting stent versus durable polymer drug‐eluting stents in high‐risk patients undergoing PCI : TWILIGHT‐SYNERGY

Author

Baber, Usman, primary, Chandiramani, Rishi, additional, Mehta, Shamir R., additional, Sartori, Samantha, additional, Zhang, Zhongjie, additional, Claessen, Bimmer E., additional, Briguori, Carlo, additional, Sharma, Samin, additional, Dangas, George, additional, and Mehran, Roxana, additional

Published
2020
Full Text
View/download PDF

6. Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT)

Author

Ghosh‐Swaby, Olivia R., primary, Tan, Mary, additional, Bagai, Akshay, additional, Yan, Andrew T., additional, Goodman, Shaun G., additional, Mehta, Shamir R., additional, Fisher, Harold N., additional, Cohen, Eric A., additional, Huynh, Thao, additional, Cantor, Warren J., additional, Le May, Michel R., additional, Déry, Jean‐Pierre, additional, Welsh, Robert C., additional, and Udell, Jacob A., additional

Published
2018
Full Text
View/download PDF

34. Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute ST-Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASIS-6 Trial

Author

Dokainish, Hisham, primary, Rajaram, Mahadevan, additional, Prabhakaran, Dorairaj, additional, Afzal, Rizwan, additional, Orlandini, Andres, additional, Staszewsky, Lidia, additional, Franzosi, Maria Grazia, additional, Llanos, Javier, additional, Martinoli, Elena, additional, Roy, Ambuj, additional, Yusuf, Salim, additional, Mehta, Shamir, additional, and Lonn, Eva, additional

Published
2013
Full Text
View/download PDF

35. Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients with Non‐ST‐Segment Elevation Acute Coronary Syndrome Initially Treated with Fondaparinux: Results from an International, Multicenter, Randomized Pilot Study (SWITCH III)

Author

WAKSMAN, RON, primary, BERTRAND, OLIVIER, additional, DRIESMAN, MITCHELL, additional, GRUBERG, LUIS, additional, ROSSI, JOSEPH, additional, MEHTA, SHAMIR, additional, SWYMELAR, STACY, additional, DVIR, DANNY, additional, XUE, ZHENYI, additional, and TORGUSON, REBECCA, additional

Published
2012
Full Text
View/download PDF

36. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).

Author

Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, Swymelar S, Dvir D, Xue Z, and Torguson R

Subjects
Acute Coronary Syndrome surgery, Aged, Angioplasty, Balloon, Coronary methods, Anticoagulants adverse effects, Antithrombins adverse effects, Female, Fondaparinux, Hemorrhage chemically induced, Hemorrhage drug therapy, Heparin adverse effects, Hirudins adverse effects, Humans, Male, Middle Aged, Peptide Fragments adverse effects, Percutaneous Coronary Intervention methods, Pilot Projects, Polysaccharides adverse effects, Prospective Studies, Recombinant Proteins adverse effects, Recombinant Proteins therapeutic use, Treatment Outcome, Acute Coronary Syndrome drug therapy, Angioplasty, Balloon, Coronary adverse effects, Anticoagulants therapeutic use, Antithrombins therapeutic use, Heparin therapeutic use, Peptide Fragments therapeutic use, Percutaneous Coronary Intervention adverse effects, Polysaccharides therapeutic use
Abstract

We aimed to determine the optimal adjunctive anticoagulation regimen for percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS) initially treated with fondaparinux. The optimal adjunctive anticoagulation regimen for PCI in these patients is unclear. In this open-label, prospective, randomized, multicenter pilot study, we compared treatment with unfractionated heparin (UFH) versus bivalirudin in patients with non-ST-segment elevation ACS initially treated with fondaparinux and undergoing early invasive strategy. The randomized population consisted of 100 patients (62.7 ± 12.7 years, 68% men), all of whom were on clopidogrel. During the angioplasty, patients were randomized to either bivalirudin or UFH therapy in a 1:1 fashion. Baseline clinical and angiographic characteristics were similar except for a higher body mass index in the UFH group (29.4 ± 4.7 vs. 27.3 ± 4.2, P = 0.02). Major bleeding was the primary outcome; a major bleeding event was documented in only 1 patient from the bivalirudin group (2%) and in none from the UFH group (P = 0.49). There was no death, Q-wave MI, or acute revascularization in either group. There was no documentation of stent thrombosis, reinfarction, and catheter thrombus. Data from this prospective, multicenter pilot study suggest that bivalirudin, compared to standard-dose UFH, has a similar safety profile in terms of peri-PCI bleeding and thrombotic events and can be used safely in ACS patients initially treated with upstream fondaparinux who undergo PCI., (©2012, Wiley Periodicals, Inc.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results